Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis
Recruiting
- Conditions
- Explore the Consistency of Drug Sensitivity Between Primary Colorectal Cancer and Liver Metastases
- Registration Number
- NCT05183425
- Lead Sponsor
- Changhai Hospital
- Brief Summary
Accumulating evidence indicates that patient- derived organoids (PDOs) can predict drug responses in the clinic. Metastasis is the main cause of death in colorectal cancer patients, and the treatment of patients with liver metastasis remains poor. Tumor heterogeneity is the cause of treatment failure. In this study, we aim the investigate the consistency of drug sensitivity for the matched primary and metastatic tumor in patients with liver metastasis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Histologically proven colorectal cancer with liver metastasis
- Aged between 18 and 70 years
- Written informed and signed consent
- Accessible to surgery sample of metastasis and primary tumor
Exclusion Criteria
- Less than 18 years and older than 70 years
- Not able to give informed consent
- Not accessible to surgery sample
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The consistency of drug sensitivity 3 years To test the consistency of drug sensitivity of primary tumor and its matched liver metastasis
- Secondary Outcome Measures
Name Time Method The establishment of PDO 3 years To test the rate of PDO derived from primary and matched metastatic colorectal cancer .
Trial Locations
- Locations (1)
Department of Colorectal Surgery in Changhai Hospital
🇨🇳Shanghai, Shanghai, China